Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated AI claims align with the provided FDA label excerpts regarding indication, mutation amenable to exon 51 skipping, genetic test dependency (implied), and mechanism of action (binding to exon 51 pre-mRNA leading to exon 51 exclusion/skipping). Minor mechanistic phrasing differences do not materially conflict.
Category Scores
Accurate Statements
Eteplirsen is a drug used in Duchenne muscular dystrophy (DMD).
1 INDICATIONS AND USAGE: “EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD)…”
Eteplirsen is used in DMD patients who have a specific genetic mutation associated with skipping exon 51.
1 INDICATIONS AND USAGE: “...patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.”
Eteplirsen is designed to help increase production of a truncated form of dystrophin by redirecting how dystrophin pre-mRNA is spliced.
12.1 Mechanism of Action: “designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing…”; 1 INDICATIONS AND USAGE: accelerated approval based on “increase in dystrophin in skeletal muscle”.
Eteplirsen is indicated for Duchenne muscular dystrophy patients with a mutation amenable to exon 51 skipping.
1 INDICATIONS AND USAGE (verbatim indication language).
Eligibility for eteplirsen depends on a genetic test result showing an exon 51–skipping–amenable variant.
1 INDICATIONS AND USAGE: “confirmed mutation of the DMD gene that is amenable to exon 51 skipping.” (Label requires a confirmed mutation; the claim’s “genetic test result” is consistent with this requirement, though the label excerpt does not explicitly say “genetic test”.)
Eteplirsen targets the mRNA splicing step to promote exon 51 skipping.
12.1 Mechanism of Action: “exclusion of this exon during mRNA processing…” and “Exon skipping is intended to allow for production of an internally truncated dystrophin protein”.
Promoting exon 51 skipping allows the body to produce a dystrophin protein closer to the shorter-but-functional form created by exon skipping.
12.1 Mechanism of Action: “Exon skipping is intended to allow for production of an internally truncated dystrophin protein…”
Unsupported Statements
Contradictions
Important Omissions
No omission assessed because the user did not ask about dosing, contraindications, warnings, adverse reactions, administration details, or storage—only indication/mechanism-related claims were provided.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated were limited to indication and mechanism of action; no dosing or safety-related assertions were made in the provided response claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One claim interprets “confirmed mutation … amenable to exon 51 skipping” as explicitly dependent on a “genetic test result”; the excerpt does not explicitly mention “genetic test,” though the confirmation requirement supports the concept.
Suggested Improvement
Rephrase to “patients with a confirmed DMD gene mutation amenable to exon 51 skipping” without explicitly stating “genetic test result,” unless the full label text explicitly describes testing.